Singapore-based medical technology Biolidics Limited is tapping the SGX Catalist market by issuing 27.5 million placement shares at S$0.28 apiece to raise approximately S$7.7 million ($5.6 million) in gross proceeds from the IPO.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
